Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 436

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Reduction of suicidality during clozapine treatment of neuroleptic- resistant schizophrenia: impact on risk-benefit assessment

· 1995 · American Journal of Psychiatry

Abstract

OBJECTIVE: Suicide has been reported to occur in 9%-13% of schizophrenic patients. It has been suggested that neuroleptic-resistant or neuroleptic-intolerant schizophrenic patients are at higher risk for suicide than neuroleptic-responsive patients. Clozapine is the treatment of choice for neuroleptic-resistant patients, but its use has been greatly limited because of its ability to cause potentially fatal agranulocytosis. The purpose of this study was to compare the suicidality of neuroleptic-resistant and neuroleptic-responsive patients and to determine if clozapine treatment decreased suicidality in the former group. METHOD: Prior episodes of suicidality were assessed in a total of 237 neuroleptic-responsive and 184 neuroleptic-resistant patients with schizophrenia or schizoaffective disorder. Eighty-eight of the neuroleptic-resistant patients were treated with clozapine and prospectively evaluated for suicidality for periods of 6 months to 7 years. RESULTS: There was no significant difference in prior suicidal episodes between neuroleptic-responsive and neuroleptic-resistant patients. Clozapine treatment of the neuroleptic-resistant patients during the follow-up period resulted in markedly less suicidality. The number of suicide attempts with a high-probability of success decreased from five to zero. This decrease in suicidality was associated with improvement in depression and hopelessness. CONCLUSIONS: These results suggest a basis for reevaluation of the risk-benefit assessment of clozapine, i.e., that the overall morbidity and mortality of patients with neuroleptic-resistant schizophrenia are less with clozapine treatment than with typical neuroleptic drugs because of less suicidality. This conclusion also has implications for increasing the use of clozapine with neuroleptic-responsive patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1176/ajp.152.2.183

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 22

  1. 1950, Bleuler E: Dementia Praecox or the Group of Schizophrenias (191 1). Translated by ZinkinJ
  2. Niskanen P, 1973, Psychiatria Fennica, 223
  3. Bleuler M, 1978, The Schizophrenic Disorders: Long-Term and Family Studies
  4. Ehlinger R, 1975, Acta Psychiatr Scand (Suppl), 260, 64
  5. Kreitman, 1977, Parasuicide
  6. Krupp P, 1989, Psychopharmacology (Berl), 99, 18, 10.1007/BF00442575 · doi:10.1007/bf00442575
  7. Rhodes HM, 1988, Psychopharmacol Bull, 10, 101
  8. User's Guide, 1990, version 6
  9. 10.2307/2529309 · DOI · Paper page
  10. 10.1159/000284650 · doi:10.1159/000284650
  11. Yasuden M, 1992, Seishin Shinkeigaku Zasshi, 94, 135
  12. Sletten LW, 1972, Dis Nerv Syst, 33, 328
  13. Beisser A, 1961, Dis Nerv Syst, 22, 365
  14. 10.1097/00004714-199110000-00019 · doi:10.1097/00004714-199110000-00019
  15. Denber HC, 1957, Dis Nerv Syst, 18, 35
  16. So, 1969, Dc Alarcon R
  17. 10.1177/070674378302800407 · doi:10.1177/070674378302800407
  18. Meltzer HY, 1990, Hosp Community Psychiatry, 41, 892
  19. Beck RE, 1988, Hosp Community Psychiatry, 39, 1269
  20. 10.1176/ajp.133.2.208 · doi:10.1176/ajp.133.2.208
  21. Solomon P, 1981, Hosp Community Psychiatry, 32, 405
  22. 10.1192/bjp.148.3.310 · doi:10.1192/bjp.148.3.310

Cited by

See all 436

Metadata

Venue
American Journal of Psychiatry
Published
1995-02-01
Volume
152
Issue
2
Pages
183-190
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
OpenAlex
W80598485
Cited by
436
References
55
FWCI
15.65
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.